China Biologic Products to Report Second Quarter 2020 Financial Results
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) plans to release its second quarter 2020 financial results on August 17, 2020, after market close. A conference call will follow on August 18, 2020, at 7:30 a.m. ET to discuss these results. Investors can access the call via specified numbers for the US, international, Hong Kong, and Mainland China. The event will be available for replay after the call until August 25, 2020. China Biologic is a leading plasma-based biopharmaceutical company in China, manufacturing over 20 diverse plasma products.
- Scheduled release of second quarter 2020 financial results on August 17, 2020 indicates transparency.
- Conference call planned for detailed discussion of results enhances shareholder engagement.
- None.
BEIJING, Aug. 10, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2020 financial results on Monday, August 17, 2020 after the market closes.
The Company's management will hold a conference call at 7:30 a.m. ET on Tuesday, August 18, 2020, which is 7:30 p.m. Beijing Time on August 18, 2020, to discuss second quarter 2020 results. Listeners may access the call by dialing:
US: | 1 888 346 8982 |
International: | 1 412 902 4272 |
Hong Kong: | 800 905945 |
Mainland China: | 4001 201203 |
A telephone replay will be available one hour after the conclusion of the conference call through August 25, 2020. The dial-in details are:
US: | 1 877 344 7529 |
International: | 1 412 317 0088 |
Passcode: | 10147239 |
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.
About China Biologic Products Holdings, Inc.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. Since the acquisition of TianXinFu (Beijing) Medical Appliance Co., Ltd. in 2018, China Biologic is also engaged in the sale of medical devices, primarily regenerative medical biomaterial products. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.
Contact:
China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Email: ir@chinabiologic.com
The Foote Group
Mr. Philip Lisio
Phone: +86-135-0116-6560
E-mail: phil@thefootegroup.com
View original content:http://www.prnewswire.com/news-releases/china-biologic-products-to-report-second-quarter-2020-financial-results-301108952.html
SOURCE China Biologic Products Holdings, Inc.
FAQ
When will China Biologic Products report its second quarter 2020 financial results?
What time is the conference call for discussing the second quarter 2020 results?
How can I access the conference call for China Biologic's financial results?
Is there a replay available for the conference call?
